In prostate cancer, therapeutically targeting this stress response via inhibition of phosphorylated eukaryotic initiation factor 2 α (P-eIF2α) promoted a cytotoxic response in metastatic prostate PDXs [48]. Here, EIF2A is linked to prostate carcinoma.